Genexine (XKRX:095700) Change In Receivables : ₩11,653 Mil (TTM As of Mar. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Genexine Change In Receivables?

Genexine's change in receivables for the quarter that ended in Mar. 2024 was ₩11,525 Mil. It means Genexine's Accounts Receivable declined by ₩11,525 Mil from Dec. 2023 to Mar. 2024 .

Genexine's change in receivables for the fiscal year that ended in Dec. 2023 was ₩1,991 Mil. It means Genexine's Accounts Receivable declined by ₩1,991 Mil from Dec. 2022 to Dec. 2023 .

Genexine's Accounts Receivable for the quarter that ended in Mar. 2024 was ₩580 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Genexine's Days Sales Outstanding for the three months ended in Mar. 2024 was 25.51.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Genexine's liquidation value for the three months ended in Mar. 2024 was ₩-24,385 Mil.

Genexine Change In Receivables Historical Data

The historical data trend for Genexine's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genexine Change In Receivables Chart

Genexine Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-862.72

-221.60

731.23

-9,252.28

1,990.61

Genexine Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															1,862.43	289.38	-1,020.51	859.31	11,524.80

Genexine Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩11,653 Mil.

Genexine (XKRX:095700) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Genexine's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	579.506	/	2073.219	*	91
=	25.51

2. In Ben Graham's calculation of liquidation value, Genexine's accounts receivable are only considered to be worth 75% of book value:

Genexine's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	52500.579	-	77320.655	+	0.75 * 579.506	+	0.5 * 0
=	-24,385

Genexine Change In Receivables Related Terms

Thank you for viewing the detailed overview of Genexine's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Genexine (XKRX:095700) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genexine Inc (XKRX:095700) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

700 Daewangpangyo-ro, Gyeonggi-do, Korea Bio Park Building B, Bundang-gu, Seongnam-si, KOR, 13488

Website

http://www.genexine.com

Genexine Inc is a clinical-stage biotechnology company. It is focused on the development and commercialization of immunotherapeutics and next-generation long-acting biologics. Its primary technologies are Therapeutic DNA vaccine technology and Hyfc platform. The company's product pipeline includes products such as GX-H9, GX-E2, GX-G3, GX-G6, and Papitrol-188 among others.

Genexine (XKRX:095700) Headlines

No Headlines